Studies ublituximab safety in older adults with relapsing multiple sclerosis
Observes infection rates in older adults with relapsing multiple sclerosis receiving ublituximab.
Plain-language title generated from the registry record
Registry title: A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)
Key facts
- Where
- Foxborough, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 55 and 80 years old?
Source: NCT06681623, who can take part
Where in United States
- Neurology Center of New England P.C.Foxborough, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Neurology Center of New England P.C.
- Trial code
- NCT06681623
- Record updated
- 18 November 2024
- Original description
The purpose of this study is to evaluate the safety of ublituximab use in the older MS adult population, as measured by incidence of infection rateRead full original descriptionShow less
A Single-Center, Prospective Cohort Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)
The purpose of this study is to evaluate the safety of ublituximab use in the older MS adult population, as measured by incidence of infection rate
Inclusion: Signed informed consent; Aged 55-80 years old; Diagnosis of RMS according to the 2017 Revised McDonald criteria; Anticipated to begin treatment with or newly treated with ublituximab (within 6 months prior to study entry) according to the local label.
Exclusion: Received initial dose of ublituximab more than 6 months prior to study entry; Evidence of clinically significant chronic or ongoing active viral, bacterial, or fungal infectious disease requiring long term systemic treatment, or any history of recurrent infection within 6-12 months prior to initiation of ublituximab; History of life-threatening infusion reaction on any anti-CD20 therapy; Active participation in an interventional clinical trial for MS.